VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals
Prismo Metals Assay Results at Silver King Show Highs of 1.73% copper, 30 ppm molybdenum, 1,362 g/t silver, 4.1% lead, and 1.3 g/t gold
